Výsledky vyhledávání - "Andrew Greenspan"

Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study

Autor: Sergio Schwartzman, Andrew Greenspan, Soumya D. Chakravarty, Stephen Xu, Jeffrey R. Curtis, Wayne Langholff, S. Kafka, Shawn Black, D. Parenti

Publikováno v: Rheumatology and Therapy

Objective Evaluate tolerability and effectiveness of golimumab-IV versus infliximab in patients with rheumatoid arthritis (RA) in a real-world setting. Methods AWARE, a prospective, real-world, pragmatic, observational, multicenter, phase 4 study, en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f94fc0852d4b03e239a3b80d5bc160e0
https://doi.org/10.1007/s40744-021-00354-4

Zobrazit plný text záznamu

Plný text ve formátu HTML

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR

Autor: Steven Fakharzadeh, Alice B. Gottlieb, Bruce Strober, Jesse A. Berlin, Kim A. Papp, Jonathan Uy, Richard G. Langley, Emily S. Brouwer, Robert Bissonnette, Wayne Langholff, Craig L. Leonardi, Kim Parnell Lafferty, Andrew Greenspan, David M. Pariser

Publikováno v: Drug Safety

Introduction Psoriasis Longitudinal Assessment and Registry (PSOLAR) was designed in 2007 as the first disease-based registry for patients with psoriasis. Objective The aim of this study was to discuss methodological limitations and post hoc analyses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1227de0316c1b456cfebb5474bf2b194
https://pubmed.ncbi.nlm.nih.gov/34075572

Zobrazit plný text záznamu

Phase 2a, randomized, double‐blind, placebo‐controlled, multicentre, parallel‐group study of an H 4 R‐antagonist ( JNJ ‐39758979) in adults with uncontrolled asthma

Autor: Matthew J. Loza, Xie Xu, Bei Zhou, R. L. Thurmond, P. E. Silkoff, Andrew Greenspan, Elliot S. Barnathan, Bin Chen, A. Kollmeier, J.Z. Jiang

Publikováno v: Clinical & Experimental Allergy. 48:957-969

Background The effects of H4 R antagonists in preclinical asthma models support the study of antagonists of the H4 R in the treatment of asthma in humans. JNJ-39758979 is a potent and highly selective oral H4 R antagonist. Objective We sought to eval

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d0c94134b792e7b2018127980ae12692
https://doi.org/10.1111/cea.13154

Zobrazit plný text záznamu

Plný text ve formátu HTML

Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies

Autor: Josef S. Smolen, Ting Ting Ge, B. Zhou, Tsutomu Takeuchi, Waldemar Radziszewski, Yoshiya Tanaka, Dace Pavlova, Ye Miao, Bin Chen, Andrew Greenspan, Christopher T. Ritchlin, Robin L. Thurmond, Daniel Baker, Xie L. Xu

Publikováno v: The Journal of Rheumatology. 43:1637-1642

Objective.To assess toreforant (selective histamine H4 receptor antagonist) in active rheumatoid arthritis (RA).Methods.In a phase IIa, double-blind, placebo-controlled test, 86 patients were randomized (2:1) to once-daily toreforant 100 mg or placeb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ed644351349a35885a1b623cf8ceb2
https://doi.org/10.3899/jrheum.160164

Zobrazit plný text záznamu

Biodynamic response prediction in breast cancer patients receiving neoadjuvant chemotherapy

Autor: John J. Turek, John R. Woods, Travis Morgan, Eric Manahan, Timothy Goedde, Eric Whitacre, Andrew Greenspan, David M. Loesch, David D. Nolte, Ran An, William Burak

Publikováno v: Journal of Clinical Oncology. 38:e12643-e12643

e12643 Background: Biodynamic signatures (temporal patterns of microscopic motion within a three-dimensional tumor explant) offer a phenomic biomarker that is highly predictive for therapeutic response. The purpose of this study is to evaluate predic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6293b64451370cae74e73ccaddf3808e
https://doi.org/10.1200/jco.2020.38.15_suppl.e12643

Zobrazit plný text záznamu

Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis

Autor: Xie L. Xu, Mamitaro Ohtsuki, Cynthia Guzzo, Yoko Murata, Katsuya Hisamichi, Takeshi Kato, Mai Kato, Chiun Fang Chiou, Hisayuki Kikuchi, Andrew Greenspan, Robin L. Thurmond, Masutaka Furue, Michael Song

Publikováno v: The Journal of Dermatology. 42:129-139

This trial was conducted to evaluate the safety and efficacy of the H4 R-antagonist JNJ-39758979 in adult Japanese patients with moderate atopic dermatitis (AD). Eligible patients were randomly assigned to JNJ-39758979 300 mg, 100 mg or placebo once

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b1d7109af8404cfd9ad607808363193
https://doi.org/10.1111/1346-8138.12726

Zobrazit plný text záznamu

Clinical and Preclinical Characterization of the Histamine H4 Receptor Antagonist JNJ-39758979

Autor: David La, Karlsson Lars, Peter Ward, Paul J. Dunford, Robin L. Thurmond, Xie L. Xu, Andrew Greenspan, Bin Chen

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 349:176-184

The histamine H4 receptor (H(4)R) has been shown to have preclinical involvement in both inflammatory and pruritic responses. JNJ-39758979 [(R)-4-(3-amino-pyrrolidin-1-yl)-6-isopropyl-pyrimidin-2-ylamine] is a potent and selective H(4)R antagonist wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1318afdb499240329d98c3ea16864689
https://doi.org/10.1124/jpet.113.211714

Zobrazit plný text záznamu

Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients

Autor: David I. Quinn, Justin Budka, Mark Tann, Heather Burney, Hao Liu, Andrew Greenspan, Roberto Pili, James W. Fletcher, Nabil Adra, Nur P. Damayanti, Sara I Edwards, Noah M. Hahn, Mark A. Green, Theodore F. Logan, Costantine Albany

Publikováno v: Journal of Clinical Oncology. 37:2572-2572

2572 Background: Immunosuppressive factors such as regulatory T cells (Tregs) and myeloid-derived suppressive cells (MDSCs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been shown to have immunomodulatory effects.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a4114465915c8db859d6cf0fe3c7519
https://doi.org/10.1200/jco.2019.37.15_suppl.2572

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání